Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA

Executive Summary

Assigning official goal dates to ANDAs that hadn't been included in GDUFA began in mid-October and already has lead to approvals.

You may also be interested in...



There's The Bolus! ANDA Sponsors Race To Avoid User Fee Spike

In a year defined by application surges, more than 200 ANDAs were submitted in September, the last month of fiscal year 2017, likely to avoid paying a much higher application fee instituted Oct. 1.

GDUFA II Will Include Small Business Relief, Priority ANDA Reviews

Generics industry and FDA have resolved remaining issues regarding financing of user fee program.

FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods

Office of Generic Drugs reviewed more than 90% of official GDUFA backlog of pending applications, but many still will require more work.

Related Content

Topics

UsernamePublicRestriction

Register

GB002090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel